Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 9/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.69 |
| ▸ | EGFR | P00533 | 3/20 | 0.69 |
| ▸ | INSR | P06213 | 1/20 | 0.69 |
| ▸ | LCK | P06239 | 1/20 | 0.69 |
| ▸ | NSD2 | O96028 | 2/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.44 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401376 | 1.00 | PDGFRB (0.69) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL1401362 | 1.00 | PDGFRB (0.69) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL1401377 | 1.00 | PDGFRB (0.69) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL6896442 | 0.84 | PDGFRB (0.97) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL3393843 | 0.83 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL842647 | 0.83 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL842648 | 0.83 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL6896444 | 0.82 | PDGFRB (0.97) | PDGFRBPDGFRAEGFRINSRLCK | |
| Hydrochloric Acid SCHEMBL1401374 | 0.82 | PDGFRB (0.97) | PDGFRBPDGFRAEGFRINSRLCK | |
| Hydrochloric Acid SCHEMBL7872629 | 0.82 | PDGFRB (0.97) | PDGFRBPDGFRAEGFRINSRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001945-B1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | AVENTIS PHARMA INC (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-1001946-B1 | QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | AVENTIS PHARMA INC (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1687642-B1 | Screening methods for combinations of biological compounds | CENTELION (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070197538-A1 | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-08-23 | — | — | US | disclosed |
| US-6852712-B2 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-6821962-B2 | CONTROLLING CELL DIFFERENTIATION; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2004-11-23 | — | — | US | disclosed |
| US-6696434-B2 | CONTROLLING CELL DIFFERENTIATION, CELL PROLIFERATION | AVENTIS PHARMACEUTICALS INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030139399-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. | 2003-07-24 | — | — | US | disclosed |
| US-20030139400-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2003-07-24 | — | — | US | disclosed |
| US-20030130285-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. | 2003-07-10 | — | — | US | disclosed |
| US-6528526-B1 | Inhibition of cell proliferation and/or cell matrix production and/or cell movement (chemotaxis) and/or T cell activation and proliferation | AVENTIS PHARMACEUTICALS INC. | 2003-03-04 | — | — | US | disclosed |
| US-6482834-B2 | ANTIPROLIFERATION AGENTS; ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2002-11-19 | — | — | US | disclosed |
| US-20010023250-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-09-20 | — | — | US | disclosed |
| US-6245760-B1 | ANTICANCER AGENTS; ANTIINFLAMMATORYA GENTS; SKIN DISORDERS | AVENTIS PHARMACEUTICALS PRODUCTS, INC | 2001-06-12 | — | — | US | disclosed |
| US-6180632-B1 | USE OF THESE COMPOUNDS FOR TREATING DISORDERS/CONDITIONS INVOLVING CELLULAR DIFFERENTIATION, PROLIFERATION, EXTRACELLULAR MATRIX PRODUCTION OR MEDIATOR RELEASE AND/OR T CELL ACTIVATION AND PROLIFERATION | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139400-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases | LCK, LTK, PTK6 | PDGFRB 27/4885PDGFRA 32/4885EGFR 1365/4885 |
| US-20030130285-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, PTK6 | PDGFRB 27/4885PDGFRA 32/4885EGFR 1365/4885 |
| US-20070197538-A1 | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors | MCL1, ABL1, TIE1 | PDGFRB 13/4885PDGFRA 10/4885EGFR 116/4885 |
| US-20010023250-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, PTK6 | PDGFRB 27/4885PDGFRA 32/4885EGFR 1365/4885 |
| US-20030139399-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, PTK6 | PDGFRB 27/4885PDGFRA 32/4885EGFR 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.